These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25245375)

  • 1. Development of EGFR family small molecule inhibitors for anticancer intervention: an overview of approved drugs and clinical candidates.
    Cheng W; Hu Y; Sheng R
    Curr Med Chem; 2014; 21(38):4374-404. PubMed ID: 25245375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy.
    Cheng W; Zhou J; Tian X; Zhang X
    Curr Med Chem; 2016; 23(29):3343-3359. PubMed ID: 27160532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
    Dhomen NS; Mariadason J; Tebbutt N; Scott AM
    Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors.
    Cheng W; Wang M; Tian X; Zhang X
    Eur J Med Chem; 2017 Jan; 126():476-490. PubMed ID: 27914362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting EGFR in pancreatic cancer treatment.
    Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
    Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into the medicinal chemistry of EGFR and HER-2 inhibitors.
    Wang C; Gao H; Dong J; Wang F; Li P; Zhang J
    Curr Med Chem; 2014; 21(11):1336-50. PubMed ID: 24251571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the EGF/HER Ligand-Receptor System in Cancer.
    Esparís-Ogando A; Montero JC; Arribas J; Ocaña A; Pandiella A
    Curr Pharm Des; 2016; 22(39):5887-5898. PubMed ID: 27426127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor as a target for anti-cancer agent design.
    Cao J; Fang H; Wang B; Ma C; Xu W
    Anticancer Agents Med Chem; 2010 Jul; 10(6):491-503. PubMed ID: 20698825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress.
    Sharma B; Singh VJ; Chawla PA
    Bioorg Chem; 2021 Nov; 116():105393. PubMed ID: 34628226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting ErbB receptors in high-grade glioma.
    Berezowska S; Schlegel J
    Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virtual high throughput screening of natural peptides against ErbB1 and ErbB2 to identify potential inhibitors for cancer chemotherapy.
    Patnaik SK; Ayyamperumal S; Jade D; Palathoti N; Akey KS; Jupudi S; Harrison MA; Ponnambalam S; Mj N; Mjn C
    J Biomol Struct Dyn; 2024 Jul; 42(11):5551-5574. PubMed ID: 37387589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.
    Hojjat-Farsangi M
    Int J Mol Sci; 2014 Aug; 15(8):13768-801. PubMed ID: 25110867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism.
    Abourehab MAS; Alqahtani AM; Youssif BGM; Gouda AM
    Molecules; 2021 Nov; 26(21):. PubMed ID: 34771085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
    Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
    Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of action and preclinical development of afatinib].
    Diz Taín P; González AL; García-Palomo A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():7-11. PubMed ID: 27426242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review on EGFR Inhibitors: Critical Updates.
    Singh D; Attri BK; Gill RK; Bariwal J
    Mini Rev Med Chem; 2016; 16(14):1134-66. PubMed ID: 26996617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds.
    Yu-Jing YJ; Zhang CM; Liu ZP
    Anticancer Agents Med Chem; 2012 May; 12(4):391-406. PubMed ID: 22043991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.